Statistical analysis plan of a randomized controlled trial to compare a restrictive strategy to usual care for the effectiveness of cholecystectomy (SECURE trial) by Wennmacker, S.Z. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/200404
 
 
 
Please be advised that this information was generated on 2019-06-02 and may be subject to
change.
UPDATE Open Access
Statistical analysis plan of a randomized
controlled trial to compare a restrictive
strategy to usual care for the effectiveness
of cholecystectomy (SECURE trial)
Sarah Z. Wennmacker1, Aafke H. van Dijk2, Joost P. H. Drenth3, Sandra C. Donkervoort4, Djamila Boerma5,
Gert P. Westert6, Cornelis J. H. M. van Laarhoven1, Marja A. Boermeester2, Marcel G. W. Dijkgraaf7 and
Philip R. de Reuver1*
Abstract
Background: Cholecystectomy is the preferred treatment for symptomatic cholecystolithiasis. However, persistent
pain after cholecystectomy for symptomatic cholecystolithiasis is reported in up to 40% of patients. The aim of the
SECURE trial is to compare the effectiveness of usual care with a restrictive strategy using a standardized work-up
with stepwise selection for cholecystectomy in patients with gallstones and abdominal complaints. The SECURE trial
is designed as a multicenter, randomized, parallel-arm, non-inferiority trial in patients with abdominal symptoms
and ultrasound-proven gallstones or sludge. Randomization was performed to either usual care (standard practice,
according to the physician’s knowledge and experience, and physician’s and patient’s preference) or a restrictive
standardized strategy: treated with interval evaluation and stepwise selection for laparoscopic cholecystectomy
based on fulfilment of pre-specified criteria. This article presents in detail the statistical analysis plan (SAP) of this
trial and was submitted before outcomes were available to the investigators.
Results: The primary end point of this trial is defined as the proportion of patients being pain-free at 12 months’
follow-up. Pain will be assessed with the Izbicki Pain Score. Secondary endpoints will be the proportion of patients
with complications due to gallstones or cholecystectomy, quality of life, the association between the patients’
symptoms and treatment, work performance, and cost-effectiveness.
Discussion: The data from the SECURE trial will provide evidence whether or not a restrictive strategy in patients
with symptomatic cholecystolithiasis is associated with similar patient reported outcomes and a reduction in the
number of cholecystectomies compared to usual care. The data from this trial will be analyzed according to this
pre-specified SAP.
Trial registration: The Netherlands National Trial Register NTR4022. Registered on 5 June 2013.
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Introduction
Despite the high number of cholecystectomies for symp-
tomatic cholecystolithiasis performed worldwide, this ap-
proach appears to be ineffective as up to 40% of patients
will continue to have (persistent) abdominal pain [1, 2].
The SECURE trial is designed to examine the effectiveness
of usual care versus restrictive strategy in patients with
symptomatic gallstones. The trial protocol was previously
published [3] and present article is the proposed statistical
analysis plan (SAP). The SAP was written by the investiga-
tors before any of the outcomes were available.
Summary study protocol
The SECURE trial (Scrutinizing (in)efficient use of chole-
cystectomy: a randomized trial concerning variation in prac-
tice) is designed as a multi-centre, randomized, parallel-arm,
non-inferiority study in 1038 subjects with abdominal
symptoms and ultrasound-proven gallstones or sludge.
All patients between the age of 18 and 95 who are re-
ferred to a surgical outpatient clinic for treatment of
ultrasound-proven gallstones or sludge, and abdominal
complaints are suitable for inclusion. Exclusion criteria
are (a) a history of complicated cholelithiasis; (b) an indi-
cation for primary open cholecystectomy; (c) a history of
current malignancy; (d) an expected short life span of less
than 12 months; (e) an American Society of Anaesthesiol-
ogists physical status classification (ASA) of III and IV; (f)
known liver cirrhosis; (g) cognitive disorders that predis-
pose unreliable questionnaire responses; (h) insufficient
knowledge of the Dutch language and (i) pregnancy.
After inclusion, patients will be randomized to either
usual care or to the restrictive strategy. Patients assigned
to the usual care group will receive the standard care
given at the participating centres. Treatment decisions (i.e.
cholecystectomy or conservative treatment) will be based
on the physician’s knowledge, preference and experience,
and on the patients’ preferred choice of treatment. The re-
strictive strategy includes a stepwise selection for surgery,
using a triage instrument for symptomatic cholecysto-
lithiasis. In this restrictive strategy, patients are selected
for cholecystectomy on fulfilment of pre-specified criteria
of the triage instrument: biliary colic defined by the Rome
criteria, pain radiating to the back and a positive pain re-
sponse to simple analgesics. Patients not fulfilling the
pre-specified criteria are selected for conservative treat-
ment and further work-up of alternative diagnoses for the
abdominal complaints. Patients will be evaluated at the
outpatient clinic every 3 months. Patients in the restrictive
strategy with conservative treatment can be indicated for
cholecystectomy at such an evaluation if the symptoms
develop and match the pre-specified criteria, or if all other
causes for abdominal pain are excluded.
The primary outcome is defined as the proportion of pa-
tients being pain-free at 12 months’ follow-up (irrespective
of treatment). Pain and pain medication use will be
assessed with the Izbicki Pain Score (IPS). Non-inferiority
of the restrictive strategy to the usual care will be assessed,
with a non-inferiority margin of 5% (i.e. significance level).
Secondary endpoints include number of cholecystecto-
mies, time to pain-free, complications due to gallstones or
cholecystectomy, patient-reported satisfaction on treat-
ment outcome, alternative diagnostics and treatment, pa-
tients’ health status over time, working disability, the
association between the patients’ symptoms and treat-
ment, practice variation, and cost-effectiveness. Safety out-
comes are complications of treatment, and serious adverse
events (SAEs).
A total of 1038 evaluable patients should be included
in this study. For power analysis, we assumed that the
percentage of pain-free patients after 12 months in the
restrictive strategy would be at least equal to the usual
care, and that in the usual care a maximum of 80% of
patients would be pain-free after 12 months. Restrictive
strategy would be considered non-inferior if at least 75%
of patients are pain-free. Possible contamination of the
usual care by the restrictive strategy might increase the
percentage of patients being pain-free (e.g. by 1%), and
the non-inferiority boundary should increase equally.
Therefore, with a one-sided Z-test, power of 80% and
significance level of 5%, 1038 evaluable patients (519 per
arm) need to be included. In absence of contamination
this would result in a power of 89%. On 26 April 2017,
all patients will be included and the completed
follow-up is expected in May 2018. The power analysis
and other study procedures are further detailed in the
previously published trial protocol [3].
Protocol developments
The SECURE trial is registered at the Netherlands
National Trial Register (NTR4022) on 5 June 2013. The
Institutional Review Board of the Academic Medical
Centre, Amsterdam, approved the protocol on 7 August
2013, and 24 participating centres were added in the
course of the study, located throughout The Netherlands.
Statistical analysis plan
General principles
The analyses will be performed after last patient out, after
monitoring and cleaning of data gathered from all pa-
tients, and after acceptance of this SAP for publication.
Analyses will be performed by the investigators and bio-
statistician of the SECURE study group, using the latest
version of SPSS statistics (IBM Corp., Armonk, NY, USA).
Patient flow diagram
The flow of participants will be illustrated in a flow dia-
gram according the Consolidation Standard of Reporting
Trials (CONSORT) (Fig. 1).
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Intention-to-treat and per protocol population
The main analysis will be performed according the
intention-to-treat (ITT) principle. In the ITT analysis all
patients are analysed according to their initially assigned
study arm at baseline, regardless of adherence to study
protocol. Patient who withdrew consent or patients with
a protocol violation concerning eligibility are excluded
from ITT analysis. Patients with missing baseline infor-
mation on the fulfilment of the pre-specified criteria of
the triage instrument and patients lost to follow-up
(from whom no outcome data are available at any time
point (baseline, 3, 6, 9, and 12 months follow-up)) were
replaced and likewise excluded from ITT analysis. Differ-
ences in patient characteristics between patients lost to
follow-up and included patients will be assessed. In case
of potentially meaningful differences, a worst-case sce-
nario will be run, in which all patients lost to follow-up
in the usual care are considered pain-free, all patients
lost to follow-up in the restrictive strategy are consid-
ered not pain-free after 12 months, and all patients
lost-to-follow-up are added to the existing ITT analysis
group. A full, reproducible account will be provided of
what is or is not considered as potentially meaningful.
In view of the non-inferiority study design, per proto-
col (PP) analysis will also be performed. All subjects
from the ITT population without protocol violations
and deviations regarding treatment will be included in
the PP population (Fig. 2).
Protocol violations in eligibility and consent, and deviations
in treatment
Protocol violation in eligibility is defined as when a patient
was randomized, but did no longer qualify for inclusion
criteria or did meet an exclusion criterion (e.g. had cho-
ledocholithiasis or cholecystitis, was pregnant, had cancer
at baseline). These patients will be excluded from further
follow-up and analysis.
Informed consent is obtained from the patients ac-
cording to the SECURE trial protocol [3]. Patients who
withdrew their consent after randomisation will be ex-
cluded from further follow-up and analysis. The number
of excluded patients after randomisation will be dis-
played in the CONSORT flow diagram (Fig. 1).
Patients assigned to the usual care arm (control) re-
ceive the standard care given at participating centres,
based on physician’s knowledge, experience, and both,
physician’s and patient’s preferences. Deviation of the
usual care protocol is defined as when a patient is
planned for cholecystectomy, but surgery is not per-
formed during follow-up (Fig. 2).
Patients assigned to the restrictive strategy (interven-
tion) are selected for cholecystectomy on fulfilment of
the pre-specified criteria of the triage instrument, or se-
lected for further work-up if patients did not meet the
criteria of the triage instrument. The latter patients
could undergo cholecystectomy during follow-up in the
trial if abdominal symptoms developed and meet the
Fig. 1 Participants flow diagram
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criteria of the triage instrument at a later time point, or
when further work-up shows no alternative diagnosis
and gallstones are the only remaining explanation for
the symptoms. Deviation of the restrictive strategy
protocol is present if (1) patients who meet the criteria
of the triage instrument for cholecystectomy do not
undergo cholecystectomy, (2) patients who do not meet
the criteria of the triage instrument do undergo early
cholecystectomy, which does not refer to patients who
undergo further work-up that shows no alternative diag-
nosis and gallstones are the only remaining explanation
for the symptoms (Fig. 2).
Patient replacement and missing data
Based on the sample size calculation we need to include
a total of 1038 evaluable patient (519 per study arm). Pa-
tients are evaluable if they are not excluded due to
protocol violation in eligibility or consent, and if (1) the
triage instrument (with pre-specified criteria for chole-
cystectomy) at baseline is completed, and (2) primary
outcome at 12 months (either directly or through imput-
ation) is available. To reach the appropriate sample size
and targeted power in the study, patients not fulfilling
these evaluability criteria are replaced.
At the interim safety analysis in 2016, uncompleted
baseline triage instruments and violations in patients’ eli-
gibility and consent were observed. The expected rate of
patients lost to follow-up and/or patients with incomplete
data was 21%. The additional number of patients that
need to be replaced is calculated according the formula
1038 / (1 - proportion non-evaluable patients). Based on
this the total sample size was increased from 1038 to 1325
patients. Importantly, no changes were made regarding
the primary outcome and secondary outcomes.
Fig. 2 Patient inclusion for intention to treat (ITT) and per protocol (PP) analysis
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If outcome data at 12 months’ follow-up cannot be ob-
tained through patients’ questionnaires, the patient will be
contacted by telephone to retrieve the primary outcome.
Secondary outcome data of these patients and all data on
patients that cannot be contacted will be considered miss-
ing. Patients from whom no outcome data are available at
any time point (baseline, 3, 6, 9, and 12 months follow-up)
are considered lost to follow-up and will be excluded from
analysis.
Different scenarios for handling missing data will be
considered. A definitive choice for method of handling
missing data will be made based on the robustness of
the analysis results.
First, complete case analysis will be performed in which
patients with incomplete data at 12 months’ follow-up will
be excluded from analysis. Although the non-evaluable
patients are replaced, this method could lead to loss of
power and biased estimates [4]. Second, single imputation
by last observation carried forward (LOCF) will be per-
formed, using the results of the last available patients’
questionnaire (9, 6, 3 months’ follow-up or baseline).
Third, the nearest neighbour (NN) imputation will be per-
formed. The missing value will be replaced by a value ob-
tained from related cases in the cohort, either the actual
measured value from another patient (1-NN) or the aver-
age of measured values from several (k) patients (k-NN)
[5]. Lastly, multiple imputation will be performed. The co-
efficients of multiple (% of missing data) rounds of imput-
ation, based on relevant patient characteristics and
outcome predictors, will be used to obtain final estimates
of the missing value [6]. The variables selected as predic-
tors for imputation contain; sex, age, body mass index
(BMI), ASA classification, history of abdominal surgery,
study arm, treatment, fulfilment of criteria of the triage in-
strument, complications, smoking, alcohol consumption,
use of pain medication, not-pain-related abdominal
complaints, and the questionnaires of all time points. The
imputed values will be primarily estimated within the
observed range of the IPS and visual analogue scale
(VAS) pain score. In case the observed range is smaller
than the total range (IPS 0–100 and VAS pain score 0–
10 respectively), additional estimations within the total
range of IPS and VAS pain score will be performed, to
identify possible outliers.
The imputation strategy with the smallest confidence in-
tervals and with point estimates closest to the complete
case analysis results will be reported as the most robust
one.
Missing values of baseline characteristics will not be im-
puted. When displaying the baseline characteristics, the
actual denominator will be stated for dichotomous vari-
ables. For continuous variables a footnote to show the
number of patients for whom the variable was available
will be stated.
Baseline characteristics
The baseline characteristics of the included patients will
be reported per randomisation group and shown in a
baseline table (Table 1). The following characteristics will
be reported: age (years), sex (% F), BMI (kg/m2),
ASA-classification (% ASA II), history of abdominal sur-
gery (% yes), use of pain medication (% yes), type of medi-
cation (% paracetamol, nonsteroidal anti-inflammatory
drugs [NSAIDs], other) and indication medication use
(% used for gallstone symptoms), smoking (% yes, number
of packs/week), alcohol consumption (% yes, number of
glasses/week), baseline IPS, baseline VAS pain score, base-
line health utility score (derived from the EuroQol 5 dimen-
sions (EQ-5D) questionnaire) and baseline Gastrointestinal
Quality of Life Index (GIQLI) score. Dichotomous variables
will be summarised as proportion of patients with the
count divided by the total number of evaluated patients.
Continuous variables will be summarised as mean with
standard deviation in case of normal distribution and as
median with interquartile range in case of non-normal dis-
tribution. Testing for normality of data distributions will be
based on the Shapiro-Wilks test. For continuous variables a
footnote will state the number of evaluated patients.
Table 1 Baseline characteristics
Usual
care (n)
Restrictive
strategy (n)
Age, years
Sex, F (% n/N)
BMI, kg/m2
ASA-classification, II (% n / N)
History of abdominal surgery, yes (% n/N)
Use of pain medication, yes (% n/N)
Type of medication
Paracetamol, n (% n/n)
NSAID, n (% n/n)
Other, n (% n/n)
Indication of medication
Gallstone symptoms, n (% n/n)
Other indication, n (% n/n)
Smoking, n (% n/N)
Packs per week, n
Alcohol consumption, n (% n/N)
Glasses per week, n
Baseline IPS, total points
VAS pain score
Baseline Health Utility score
Baseline GIQLI-score, total points
ASA American Society of Anaesthesiologists physical status classification, BMI
body mass index, GIQLI Gastrointestinal Quality of Life Index, IPS Izbicki Pain
Score, NSAID nonsteroidal anti-inflammatory drug, VAS visual analogue scale
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Differences in baseline characteristics between study arms
will be reported as preferred by the intended journal. Differ-
ences between the study arms will then be analysed using
chi-square test, independent t test or Mann-Whitney test if
requested by the journal.
Assessment and analysis of primary outcome
The primary endpoint is defined as the proportion of pa-
tients being pain-free at 12 months’ follow-up. This end-
point is derived from the patient-reported IPS. Pain-free is
defined as IPS ≤ 10 (with a VAS pain score ≤ 4).
Non-inferiority will be established if the lower limit of the
one-sided 95% confidence interval for the proportion of
patients being pain-free at 12 months following restrictive
strategy is within the absolute 5% margin below the pro-
portion under usual care. The results of the ITT and the
PP analysis should both allow such interpretation.
In a supplementary appendix, the analyses will be re-
peated with logistic regression to take into account that
randomisation was stratified by center, sex, and body
mass index. Non-inferiority will be established if the
lower limit of the one-sided 95% confidence for the ad-
justed odds ratio of being pain-free at 12 months for pa-
tients under restrictive strategy relative to patients under
usual care exceeds the critical odds ratio corresponding
to the absolute 5% margin below the observed propor-
tion under usual care.
Assessment and analysis of secondary outcomes
The assessment and analysis of the secondary outcomes
will be discussed separately for each secondary outcome.
In all analyses, statistical uncertainties are expressed in
95% two-sided confidence intervals. A p value of < 0.05
will indicate statistical significance.
Number of cholecystectomies and number of patients being
pain-free after cholecystectomy
The total number of cholecystectomies performed after
12 months in the two study arms will be reported.
Whether a patient underwent surgery is registered by the
physician in the CRF and verified by patients’ interview
(by phone) and medical records at 12 month follow-up.
The proportion of patients being pain-free (defined as for
the primary outcome) in this subset of patients following
cholecystectomy will also be reported per study arm. The
chi-square test will be used to compare the outcomes be-
tween the study arms. These outcomes will be shown in a
secondary outcome table (Table 2).
Time to pain-free
The moment the patient is free of pain, defined as IPS ≤
10 (with a VAS score ≤ 4), can be deducted from the pa-
tients questionnaire. The IPS is measured at 3, 6, 9, and
12 months of follow-up. The first follow-up questionnaire
the patient reports an IPS ≤ 10 (with a VAS score ≤ 4) will
be considered the time to pain-free, providing that the pa-
tient remains pain-free during the remaining follow-up
period. Considering the limited number of assessments
over time, life tables will be generated for time to
pain-free. The median times to being free of pain, the
Wilcoxon Gehan statistic and the corresponding p
value will be reported in the secondary outcome table
(Table 2) with a graphical representation presented in a
supplementary appendix.
Complications of gallstones and cholecystectomy
All complications of gallstones and complications of
cholecystectomy will be reported per study arm. Compli-
cations should be reported by the physician to the trial co-
ordinator at occurrence. Occurrence of complications will
be verified with the patient at 3 months and 12 months’
follow-up, and with patient’s medical records at 12 months’
follow-up. Complications of gallstones are defined as oc-
currence of choledocholithiasis, acute cholecystitis, biliary
Table 2 Secondary outcomes
Usual
care (n)
Restrictive
strategy (n)
p
Cholecystectomy, n (%n/N)
Pain-free at 12 months, n (% n/n)
Time to cholecystectomy in weeks,
median (IQR)
Conservative treatment, (%n/N)
Pain-free at 12 months, (% n/n)
Time to pain-free, median (IQR)
Gallstone complications, n (%n/N)
Choledocholithiasis, n (%n/N)
Acute cholecystitis, n (%n/N)
Biliary pancreatitis, n (%n/N)
Cholangitis, n (%n/N)
Colic with hospitalisation, n (%n/N)
Gallstone complication preoperative, (% n/N)
Surgical complications, n (%n/N)
CDC I, n (%n/N)
CDC II, n (%n/N)
CDC III, n (%n/N)
CDC IV, n (%n/N)
CDC V, n (%n/N)
Patient-reported satisfaction, NRS
Working disability
Absence, hours
Loss of productivity, hours
Non-trial related SAEs, n (%/N)
CDC Claivien-Dindo classification, IQR interquartile range, NRS numerical rating
scale, SAE serious adverse event
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pancreatitis, cholangitis, or a biliary colic that required
hospitalisation. Although natural history of gallstones in-
cludes occurrence of complicated gallstone disease, the
number of patients with complicated gallstone disease can
differ based on the study arm and is therefore considered
as complication in this study. Surgical complications are
classified according to the Clavien-Dindo classification
(CDC) [7]. Complications will be assessed on patient level
(yes/no) and chi-square test will be used to compare the
outcomes between the study arms. In the case > 25% of
patients have multiple complications, assessment will be
performed on complication level (n per patient) using
Poisson-regression analysis. These outcomes will be
shown in the secondary outcome table (Table 2).
Patient-reported satisfaction on treatment outcome
At 12 months’ follow-up, all patients were asked to ex-
press their satisfaction on the treatment outcome (either
surgical or conservative) with a numerical rating scale
(NRS) between 0 and 10 (0 being the worst and 10 being
the best appraisal). The satisfaction on the treatment
outcome will be reported, as mean with standard devi-
ation if the data are normally distribution, and as median
with interquartile range if the data are skewed. The inde-
pendent t test or Mann-Whitney test will be used to
compare the outcome between study arms. Testing for
normality of data distributions will be based on the
Shapiro-Wilks test. The outcome will be shown in the
secondary outcome table (Table 2).
Alternative diagnostics and treatment
At 12 months’ follow-up, information on all diagnostic
procedures and treatments related to abdominal pain
were obtained, through patients’ interview (by phone)
and medical records. For the conservatively treated pa-
tients (i.e. who did not undergo cholecystectomy), the
proportion of patients that underwent alternative diag-
nostic procedures and/or treatments (including diagno-
sis) will be reported. The proportion of patients for
whom an alternative diagnosis (other than gallstones)
for the abdominal pain was determined, and type of
diagnoses, will be reported.
Health status scores over time
Changes in disease-specific quality of life and health util-
ity over time will be reported. Health status, defined by
GIQLI scores, and health utility scores, derived from the
EQ-5D-3 L profiles using the standard Dutch health
valuation algorithm [8], is available at baseline and 3, 6,
9, and 12 months follow-up. The follow-up data will be
assessed by repeated measurement analysis with baseline
data as covariate, using a generalized linear mixed
model. The results will be displayed per study arm in a
graph (Fig. 3).
Working disability
Working disability will be assessed using the Short Form
Health and Labour Questionnaire (SF-HLQ). Patients
filled out this questionnaire at baseline, 3, 6, 9, and
12 months of follow-up, which provides information on
absence from paid employment, production loss due to
lower efficiency while at work and impediments to paid or
unpaid employment. The cumulative number of hours of
absence and production loss per study arm will be re-
ported, as mean with standard deviation if the data are
normally distribution, and as median with interquartile
range if the data are skewed. The independent t test or
Mann-Whitney test will be used to compare the outcome
between study arms. Testing for normality of data distri-
butions will be based on the Shapiro-Wilks test. (Table 2).
Cost-effectiveness and budget impact analysis
A cost-effectiveness analysis (CEA) with the costs per
pain-free patient at 12 months as primary outcome
measure will be performed. Additionally, a cost-utility
analysis (CUA) will be performed with the costs per
quality-adjusted life year (QALY) as outcome. The short-
and mid-term affordability of the restrictive strategy in
patients with abdominal pain and ultrasound-proven
gallstones will be assessed from governmental, provider,
and insurer perspectives following a budget impact ana-
lysis (BIA) [9]. The cost-effectiveness analyses and BIA
will not be included in the primary article on the clinical
study results and are not further elaborated here.
Fig. 3 Example health status scores over time
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Practice variation
Practice variation in number of cholecystectomies in the
usual care arm will be assessed amongst the participa-
tion hospitals. The practice variation indicator is defined
as the number of patients with cholecystectomy on hos-
pital level per 100,000 inhabitants in the catchment area
of the hospital, and will be adjusted for relevant patient
characteristics (i.e. age, sex, BMI). Results on practice
variation will not be included in the primary article on
the clinical study results and the statistical approach will
not be elaborated here.
Additional analysis
The preoperative symptoms of the included patients and
fulfilment of the criteria of the triage instrument will be
assessed and shown per study arm. The relation between
specific patient characteristics or symptoms and (1) being
pain-free at 12 months’ follow-up and (2) undergoing a
cholecystectomy will be explored, to identify additional
patient characteristics that are associated with being
pain-free at 12 months follow-up and after cholecystec-
tomy. The following characteristics and (sets of) symp-
toms will be assessed: sex, age, BMI, center (high versus
low volume), ASA classification, history of surgery, use of
pain medication (and type), baseline VAS pain score, base-
line GIQLI score, baseline IPS, fulfilment of criteria of tri-
age instrument (fulfilment of all criteria and subset of the
criteria). The additional analyses will be performed using
logistic regression with and without study arm as
co-variable. Variables with a p value < 0.1 in univariable
analyses will be included in multivariable logistic regres-
sion analysis and reported in a supplementary appendix.
Subsequently, backward stepwise elimination will be used
as further variable selection method. The results will be
reported as adjusted odds ratio.
Safety outcomes
Safety outcomes are all SAEs due to complications of
gallstones or treatment and non-trial-related SAEs, be-
tween inclusion of the patient in the trial and 12 months
of follow-up. Complications of gallstones and treatment
are already incorporated in Table 2, as secondary out-
come. The number of non-trial related SAE’s will be
added in Table 2 and types of SAEs will be described.
Statistical analysis to compare non-trial-related SAEs be-
tween study arms is as described for complications of
gallstones and cholecystectomy.
Authorship
The two PhD fellows (AD and SW) of the SECURE
study group will share first authorship. The initiating
and coordinating investigator (PR) will be second author
and principle investigators MB and CvL will share senior
authorship as second to last (MB) and last author (CvL).
The other members of the SECURE study group will be
co-authors. The local investigators who contributed to
study design and data and manuscript discussion, and
included at least 50 patients will also be co-authors, pro-
vided that there are no author number restrictions at the
intended journal. Otherwise the local investigators with
the highest inclusion rate and fulfilling the above criteria
will be co-author. All other local investigators will be ex-
plicitly mentioned in the article as collaborators.
Discussion
The aim of the SECURE trial is to compare the effectiveness
and cost-effectiveness of usual care with a restrictive strategy
using a pre-operative work-up with stepwise selection for
cholecystectomy in patients with gallstones and abdominal
complaints. The present article presents the analyses that
will be published in the primary manuscript. This SAP was
written to prepare for future analyses (before the data are
available) and to increase transparency of scientific conduct,
thereby allowing others to comment our plans.
Symptomatic gallstone disease is a very common
condition with an estimated lifetime prevalence of 5–20%
[10, 11]. Laparoscopic cholecystectomy is the treatment of
choice to relieve symptoms, mainly abdominal pain. How-
ever, up to 40% of patients report persistent pain after sur-
gery [1, 2]. Annually, approximately 24,000 laparoscopic
cholecystectomies are performed in the Netherlands [12]
and 700,000 in the USA [13]. The total estimated
hospital-related costs of this procedure in the United
States are USD 9.9 billion (based on 700,000 cholecystec-
tomies and average hospital-related costs of USD 14,107
[14]). More than 60% of additional costs of employed pa-
tients are caused by costs related to sick leave of em-
ployees [15]. After a successful cholecystectomy time
before return to work ranges from 1 to 10 weeks [16].
Consequently, the total costs related to this operation are
many times higher than the billions of hospital-related
costs per year. This means that performing a cholecystec-
tomy without a realistic chance of a positive effect on
complaints only adds to health care costs without health
care gain. In addition, an unsuccessful cholecystectomy
with persistent abdominal complaints adds an additional
USD 555 per patient per year of medical costs and USD
361 per patient per year for sick leave from work and cor-
responding productivity loss [17]. These significant costs
indicate the potential value of a more restrictive strategy
for gallstone disease. An optimized indication for surgery
could improve patients’ health status, prevent surgical
complications, reduce health care demand and, conse-
quently, lower health care costs. Therefore, we suggested
a more restrictive strategy and hypothesized that the step-
wise selection is non-inferior to usual care with respect to
patient-reported outcome and could provide a basis to
lower the number of cholecystectomies performed [3].
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This might prevent further increase in cholecystectomy
rates reported in the last decades and reduce the geo-
graphic variation between and within countries like
France, Britain, the Netherlands and the USA [18]. The
lack of level 1 evidence for the indication of gallbladder re-
moval results in high operation rates and maintains prac-
tice variation.
Randomization in the SECURE trial was performed to
either standard practice, according to the physician’s
knowledge and experience and physician’s and patient’s
preference (usual care), or a restrictive strategy: treated
with interval evaluation and stepwise selection for
laparoscopic cholecystectomy based on fulfilment of
pre-specified criteria. A discussed pitfall of this study is
the risk of contamination of usual care by the restrictive
work-up approach. It is conceivable that specialists trans-
fer their usual care to a more restrictive work-up during
the trail. To reduce this potential bias the trial was per-
formed in more than 20 Dutch hospitals and thereby
many different surgeons were involved to avoid manifest
and uniform contamination. Potentially remaining con-
tamination was accounted for during the sample size cal-
culation of the SECURE trial [3].
At interim safety analysis (after complete follow-up of
669 patients) violation of eligibility was noticed in 72 pa-
tients (10.8%) due to lack of baseline data on the triage
instrument (not recorded by treating physician) and in
31 patients (4.6%) due to later discovered exclusion cri-
teria (e.g. pregnancy or cancer). Additionally, 36 patients
(5.4%) withdrew consent during follow-up and 6 patients
(0.9%) were lost to follow-up. Due to this loss of evalu-
able patients the total number of included patients was
increased from 1038 to 1325 patients to assure the avail-
ability of a total of 1038 evaluable patients for analysis of
the primary endpoint.
The results of this trial may optimize the clinical outcome
of gallbladder removal and reduce the number of ineffective
operations. The Secure trial has the potential to impact
daily clinical practice and improve patient outcomes. Sec-
ond, a later cost-effectiveness and budget impact analysis of
a more restrictive strategy may illustrate the cost reduction
for health care providers, insurers, and society.
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